Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
Tertiary lymphoid structures (TLS) existence is correlated with favorable prognosis in many types of cancer including non-small cell lung cancer (NSCLC). However, TLS formation and its relationship with treatment response remains unknown in NSCLC who received anti-PD-1 antibody plus chemotherapy as...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/11/e005531.full |
| _version_ | 1818467848470659072 |
|---|---|
| author | Chen Chen Jingjing Li Bin Zhang Chenguang Li Dongsheng Yue Changli Wang Xinyi Wu Weiran Liu Xiaoyan Sun Leina Sun Huilan Mo Yingnan Feng Ying Xin Zhenfa Zhang |
| author_facet | Chen Chen Jingjing Li Bin Zhang Chenguang Li Dongsheng Yue Changli Wang Xinyi Wu Weiran Liu Xiaoyan Sun Leina Sun Huilan Mo Yingnan Feng Ying Xin Zhenfa Zhang |
| author_sort | Chen Chen |
| collection | DOAJ |
| description | Tertiary lymphoid structures (TLS) existence is correlated with favorable prognosis in many types of cancer including non-small cell lung cancer (NSCLC). However, TLS formation and its relationship with treatment response remains unknown in NSCLC who received anti-PD-1 antibody plus chemotherapy as the neoadjuvant treatment (neoadjuvant chemoimmunotherapy). Here, we investigate TLS maturation and abundance in resectable NSCLC receiving neoadjuvant treatments. We retrospectively collected formalin-fixed paraffin embedded (FFPE) tissues from patients with resectable NSCLC (stage II–IIIA) from three cohorts based on treatment: naïve (N=40), neoadjuvant chemoimmunotherapy (N=40), and neoadjuvant chemotherapy (N=41). The TLS in tumor tissues was detected by immunohistochemical staining, and the differences in TLS maturation and abundance among different treatment groups were analyzed, as well as the relationship with pathological response and prognosis of patients. Multiplex immunofluorescence staining was used to explore the features of immune microenvironment. Higher major pathological response (MPR) rate and pathological complete response (pCR) rate were in the neoadjuvant chemoimmunotherapy group than in the neoadjuvant chemotherapy group (MPR: 45.0% vs 17.1%; pCR: 35.0% vs 4.9%). Among the three cohorts, neoadjuvant chemoimmunotherapy-treated NSCLCs displayed highest TLS maturation and abundance. Both the maturation and abundance of TLS were significantly correlated with MPR in both the neoadjuvant chemoimmunotherapy and the chemotherapy group. Patients with high maturation and abundance of TLS exhibited better disease-free survival (DFS) in all the three cohorts. TLS maturation was also an independent predictor for DFS in the neoadjuvant chemoimmunotherapy and treatment naïve group. Multiplex immunohistochemistry analysis using paired biopsy-surgery samples showed increased infiltration of CD8+T cell and decreased infiltration of M1 and M2 macrophages after neoadjuvant chemoimmunotherapy treatment in patients achieving MPR. There were no significant differences in features of immune cell infiltration for those with mature TLS achieving MPR when cross-compared across the three cohorts. These results demonstrate that TLS maturation is associated with MPR and an independent predictor for DFS in resectable neoadjuvant chemoimmunotherapy-treated NSCLC. The induction of TLS maturation may be a potential mechanism of action of neoadjuvant chemoimmunotherapy in resectable NSCLC. |
| first_indexed | 2024-04-13T21:04:39Z |
| format | Article |
| id | doaj.art-646bdf05f8814b70b51afa3ed9a2f817 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-13T21:04:39Z |
| publishDate | 2022-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-646bdf05f8814b70b51afa3ed9a2f8172022-12-22T02:30:00ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-11-01101110.1136/jitc-2022-005531Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancerChen Chen0Jingjing Li1Bin Zhang2Chenguang Li3Dongsheng Yue4Changli Wang5Xinyi Wu6Weiran Liu7Xiaoyan Sun8Leina Sun9Huilan Mo10Yingnan Feng11Ying Xin12Zhenfa Zhang13School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China3 University of North Carolina Project-China, Guangzhou, Guangdong, ChinaRadiology, Jinan University First Affiliated Hospital, Guangzhou, Guangdong, ChinaDepartment of Cardiology, Zhongshan Hospital, Fudan University; Shanghai Institute of Cardiovascular Diseases, Shanghai, China1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin`s Clinical Research Center for Cancer, Tianjin, China1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin`s Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Ophthalmology, Qilu Hospital, Shandong University, Jinan, China2 Department of Anesthesiology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaObstetrics and Gynecology, Beijing Daxing District People’s Hospital, Daxing Teaching Hospital, Capital Medical University, Beijing, ChinaDepartment of Pathology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin`s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin`s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin`s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of the Medical, 3D Medicines Inc, Shanghai, ChinaDepartment of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin`s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaTertiary lymphoid structures (TLS) existence is correlated with favorable prognosis in many types of cancer including non-small cell lung cancer (NSCLC). However, TLS formation and its relationship with treatment response remains unknown in NSCLC who received anti-PD-1 antibody plus chemotherapy as the neoadjuvant treatment (neoadjuvant chemoimmunotherapy). Here, we investigate TLS maturation and abundance in resectable NSCLC receiving neoadjuvant treatments. We retrospectively collected formalin-fixed paraffin embedded (FFPE) tissues from patients with resectable NSCLC (stage II–IIIA) from three cohorts based on treatment: naïve (N=40), neoadjuvant chemoimmunotherapy (N=40), and neoadjuvant chemotherapy (N=41). The TLS in tumor tissues was detected by immunohistochemical staining, and the differences in TLS maturation and abundance among different treatment groups were analyzed, as well as the relationship with pathological response and prognosis of patients. Multiplex immunofluorescence staining was used to explore the features of immune microenvironment. Higher major pathological response (MPR) rate and pathological complete response (pCR) rate were in the neoadjuvant chemoimmunotherapy group than in the neoadjuvant chemotherapy group (MPR: 45.0% vs 17.1%; pCR: 35.0% vs 4.9%). Among the three cohorts, neoadjuvant chemoimmunotherapy-treated NSCLCs displayed highest TLS maturation and abundance. Both the maturation and abundance of TLS were significantly correlated with MPR in both the neoadjuvant chemoimmunotherapy and the chemotherapy group. Patients with high maturation and abundance of TLS exhibited better disease-free survival (DFS) in all the three cohorts. TLS maturation was also an independent predictor for DFS in the neoadjuvant chemoimmunotherapy and treatment naïve group. Multiplex immunohistochemistry analysis using paired biopsy-surgery samples showed increased infiltration of CD8+T cell and decreased infiltration of M1 and M2 macrophages after neoadjuvant chemoimmunotherapy treatment in patients achieving MPR. There were no significant differences in features of immune cell infiltration for those with mature TLS achieving MPR when cross-compared across the three cohorts. These results demonstrate that TLS maturation is associated with MPR and an independent predictor for DFS in resectable neoadjuvant chemoimmunotherapy-treated NSCLC. The induction of TLS maturation may be a potential mechanism of action of neoadjuvant chemoimmunotherapy in resectable NSCLC.https://jitc.bmj.com/content/10/11/e005531.full |
| spellingShingle | Chen Chen Jingjing Li Bin Zhang Chenguang Li Dongsheng Yue Changli Wang Xinyi Wu Weiran Liu Xiaoyan Sun Leina Sun Huilan Mo Yingnan Feng Ying Xin Zhenfa Zhang Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer Journal for ImmunoTherapy of Cancer |
| title | Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer |
| title_full | Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer |
| title_fullStr | Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer |
| title_full_unstemmed | Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer |
| title_short | Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer |
| title_sort | maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non small cell lung cancer |
| url | https://jitc.bmj.com/content/10/11/e005531.full |
| work_keys_str_mv | AT chenchen maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT jingjingli maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT binzhang maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT chenguangli maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT dongshengyue maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT changliwang maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT xinyiwu maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT weiranliu maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT xiaoyansun maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT leinasun maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT huilanmo maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT yingnanfeng maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT yingxin maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer AT zhenfazhang maturationandabundanceoftertiarylymphoidstructuresareassociatedwiththeefficacyofneoadjuvantchemoimmunotherapyinresectablenonsmallcelllungcancer |